HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

DS-8273a

death receptor 5 (DR5) agonistic antibody, has cytotoxic activity against human cancer cells and induces apoptosis after specific binding to DR5

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Forero, Andres: 2 articles (06/2017 - 01/2017)
2.	Kumar, Prasanna: 2 articles (06/2017 - 01/2017)
3.	Senaldi, Giorgio: 2 articles (01/2017 - 01/2016)
4.	Bendell, Johanna: 1 article (06/2017)
5.	Condamine, Thomas: 1 article (06/2017)
6.	Dominguez, George A: 1 article (06/2017)
7.	Gabrilovich, Dmitry I: 1 article (06/2017)
8.	Hashimoto, Ayumi: 1 article (06/2017)
9.	Hockstein, Neil: 1 article (06/2017)
10.	Liu, Qin: 1 article (06/2017)

Related Diseases

1.

Neoplasms (Cancer)

01/01/2017 - "First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors."
06/15/2017 - "In tumors, DS-8273a treatment resulted in a decrease of MDSCs in 50% of the patients who were able to provide pre- and on-treatment biopsies.Conclusions"
06/15/2017 - "Selective Targeting of Myeloid-Derived Suppressor Cells in Cancer Patients Using DS-8273a, an Agonistic TRAIL-R2 Antibody."
01/01/2017 - "This phase 1 study evaluated the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of a new monoclonal antibody potent DR5 agonist, DS-8273a, in subjects with advanced solid tumors. "
01/01/2016 - "Background: DS-8273a, an anti-human death receptor 5 (DR5) agonistic antibody, has cytotoxic activity against human cancer cells and induces apoptosis after specific binding to DR5. "

Related Drugs and Biologics

1.	Monoclonal Antibodies
2.	TNF-Related Apoptosis-Inducing Ligand Receptors